Robert Coffin - Jul 2, 2021 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role
President & Chief R&D Officer, Director
Signature
/s/ Jean Franchi, attorney-in-fact
Stock symbol
REPL
Transactions as of
Jul 2, 2021
Transactions value $
-$312,712
Form type
4
Date filed
7/7/2021, 09:01 PM
Previous filing
Jun 30, 2021
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Sale -$313K -7.81K -0.44% $40.04 1.78M Jul 2, 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.13. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,775,684 shares of the Issuer's common stock. The reporting person also holds options to acquire 1,092,899 shares of the Issuer's common stock, 645,394 of which are exercisable as of the date hereof.